156 related articles for article (PubMed ID: 17599334)
1. Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia.
Pandina GJ; Canuso CM; Youssef E; Kujawa M; Mahmoud R
Hum Psychopharmacol; 2007 Jul; 22(5):326-7; author reply 328. PubMed ID: 17599334
[No Abstract] [Full Text] [Related]
2. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
Melkersson KI
Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165
[TBL] [Abstract][Full Text] [Related]
3. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Peng PW; Huang MC; Tsai CJ; Pan CH; Chen CC; Chiu CC
J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
[No Abstract] [Full Text] [Related]
4. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.
Knegtering R; Baselmans P; Castelein S; Bosker F; Bruggeman R; van den Bosch RJ
Am J Psychiatry; 2005 May; 162(5):1010-2. PubMed ID: 15863810
[TBL] [Abstract][Full Text] [Related]
5. Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone.
Segal M; Avital A; Derevenski A; Berstein S; Sandbank S; Weizman A
Int Clin Psychopharmacol; 2007 Jul; 22(4):192-6. PubMed ID: 17519641
[TBL] [Abstract][Full Text] [Related]
6. The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients.
Ohta C; Yasui-Furukori N; Furukori H; Tsuchimine S; Saito M; Nakagami T; Yoshizawa K; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):573-6. PubMed ID: 21216266
[TBL] [Abstract][Full Text] [Related]
7. Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder.
Duval F; Guillon MS; Mokrani MC; Crocq MA; Garcia Duarte F
Psychoneuroendocrinology; 2008 Feb; 33(2):255-9. PubMed ID: 18053652
[TBL] [Abstract][Full Text] [Related]
8. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
9. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
Gomeni R; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2013 Oct; 53(10):1010-9. PubMed ID: 23868656
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of combination therapy with lithium and risperidone.
Demling JH; Huang ML; Remmerie B; Mannaert E; Sperling W
Pharmacopsychiatry; 2006 Nov; 39(6):230-1. PubMed ID: 17124646
[No Abstract] [Full Text] [Related]
11. Remission of drug-induced hepatitis after switching from risperidone to paliperidone.
Paulzen M; Orfanos S; Gründer G
Am J Psychiatry; 2010 Mar; 167(3):351-2. PubMed ID: 20194492
[No Abstract] [Full Text] [Related]
12. Risperidone and breast-feeding.
Aichhorn W; Stuppaeck C; Whitworth AB
J Psychopharmacol; 2005 Mar; 19(2):211-3. PubMed ID: 15728443
[TBL] [Abstract][Full Text] [Related]
13. [Risperidone].
Zolk O; Thürauf N
Dtsch Med Wochenschr; 2003 Jun; 128(24):1353-6. PubMed ID: 12802745
[No Abstract] [Full Text] [Related]
14. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
Nesvåg R; Hendset M; Refsum H; Tanum L
Acta Psychiatr Scand; 2006 Jul; 114(1):21-6. PubMed ID: 16774657
[TBL] [Abstract][Full Text] [Related]
15. Risperidone induced galactorrhea: a case analysis.
Hariharan J; Mohsin J
WMJ; 2002; 101(8):41-3. PubMed ID: 12557612
[TBL] [Abstract][Full Text] [Related]
16. Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
Pani L; Marchese G
Expert Opin Drug Deliv; 2009 Mar; 6(3):319-31. PubMed ID: 19317589
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.
Bai YM; Chen TT; Lin WK; Chang WH; Wu B; Hung CH; Chou P; Chen JY
J Clin Psychopharmacol; 2007 Jun; 27(3):306-8. PubMed ID: 17502783
[No Abstract] [Full Text] [Related]
18. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Fowler JA; Bettinger TL; Argo TR
Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
[TBL] [Abstract][Full Text] [Related]
19. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.
Yasui-Furukori N; Saito M; Tsuchimine S; Nakagami T; Sato Y; Sugawara N; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1491-5. PubMed ID: 18579277
[TBL] [Abstract][Full Text] [Related]
20. The interaction between superoxide dismutase and prolactin is involved in response to haloperidol and risperidone treatment in schizophrenia: a double-blind and randomized study.
Zhang XY; Zhou DF; Cao LY; Wu GY; Shen YC
J Clin Psychopharmacol; 2006 Feb; 26(1):103-5. PubMed ID: 16415724
[No Abstract] [Full Text] [Related]
[Next] [New Search]
